Therapeutic Drug Monitoring of Lacosamide in Norway: Focus on Pharmacokinetic Variability, Efficacy and Tolerability

• Published in: Neurochemical research Vol. 42; no. 7; pp. 2077 - 2083
• Main Authors: Svendsen, Torleiv, Brodtkorb, Eylert, Baftiu, Arton, Burns, Margrete Larsen, Johannessen, Svein I., Johannessen Landmark, Cecilie
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.07.2017; Springer Nature B.V
• Subjects: Acetamides - blood; Acetamides - therapeutic use; Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants - adverse effects; Anticonvulsants - blood; Anticonvulsants - therapeutic use; Antiepileptic agents; Biochemistry; Biomedical and Life Sciences; Biomedicine; Cell Biology; Child; Child, Preschool; Drug dosages; Drug Monitoring - methods; Drug Resistant Epilepsy - blood; Drug Resistant Epilepsy - drug therapy; Drug Resistant Epilepsy - epidemiology; Effectiveness; Enzymes; Epilepsy; Fasting; Female; Humans; Male; Medical records; Middle Aged; Monitoring; Neurochemistry; Neurology; Neurosciences; Norway - epidemiology; Original Paper; Patients; Pharmacokinetics; Pharmacology; Pharmacovigilance; Real variables; Retrospective Studies; Seizures; Side effects; Therapeutic drug monitoring; Treatment Outcome; Variability; Young Adult; Norway; Therapeutic drug monitoring; Pharmacokinetic variability; Epilepsy; Lacosamide; Efficacy; Tolerability; Antiepileptic drugs
• ISSN: 0364-3190; 1573-6903
• DOI: 10.1007/s11064-017-2234-8

Lacosamide (LCM) is a new antiepileptic drug (AED). Experience from therapeutic drug monitoring (TDM) in clinical practice is limited. The purpose of this study is to evaluate the pharmacokinetic variability of LCM in relation to efficacy and tolerability in patients with refractory epilepsy in a real-life setting. Variables included age, gender, daily doses and serum concentrations of LCM and other AEDs from the TDM-database at the National Center for Epilepsy in Norway. Clinical data regarding efficacy and tolerability were collected from medical records. The Norwegian Prescription Database (NorPD) was used to include population-based numbers of users. TDM-data from 344 patients were included. The median dose, serum concentration, and concentration/dose (C/D)-ratio of LCM was 350 (range 25–700) mg/day, 19.7 (range 8.1–56.2) µmol/L, and 0.06 (0.02–0.82) µmol/L/mg, respectively. Serum concentrations were reduced by 28% by concomitant use of enzyme inducers and increased by 30% in patients aged >65 years. Efficacy and tolerability were assessed in 227 patients: 29% had >50% seizure reduction (eight seizure free), 30% had no effect, and 44% reported adverse effects. In Norway, there were on average 500 patients per year using LCM in this period based on NorPD. The study demonstrated pharmacokinetic variability and use of TDM of LCM in Norway. Data were collected from multiple sources for improved pharmacovigilance. Serum concentrations were influenced by enzyme inducers and ageing, indicating the usefulness of TDM. Effect and tolerability were favorable within a suggested reference range of 10–40 µmol/L given drug-fasting conditions.